OCT 19, 2017 8:00 AM PDT

WEBINAR: New viral and non-viral platforms for T-cell engineering

Speaker
  • Director, R&D, Cell Biology/Transfection at Thermo Fisher Scientific
    Biography
      Xavier de Mollerat du Jeu, Ph.D. is a Director of R&D transfection group at Thermo Fisher Scientific, working on creating and improving new nucleic acids delivery for both research and therapeutic applications. Xavier identified new DNA delivery approaches for hard to transfect cell lines and primary/stem cells and he is the inventor of Lipofectamine® 3000. Xavier's team is also focusing on new delivery solutions for CRISPR delivery, new scalable lentiviral production systems, mechanical delivery approaches for primary T cells and in vivo delivery of RNAi/mRNA for research and therapeutic application. He studied molecular biology and plant physiology at the University of Montpellier II in France, and received his Ph.D. in human genetics in 2003 from Clemson University in South Carolina. His thesis work involved identifying the gene(s) responsible for Split Hand/Split Foot Malformation 3 (SHFM 3). His post-doctoral fellowship research was in the laboratory of Dr. Michael G. Rosenfeld at UCSD, where he studied the roles of microRNAs in pituitary gland development. He joined Thermo Fisher in 2005.

    Abstract

    DATE: October 19, 2017
    TIME: 08:00am PDT, 11:00am EDT

     

    Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including:

    • New solution for small-to-large scale serum-free, suspension lentiviral production – LV-MAX™ Lentiviral Production System
      • Platform development process using Design of Experiment (DOE) methodologies
      • High-throughput to large scale bioreactor protocols
      • Cost benefits of this system over current methods
    • Novel gene editing tools for primary T cells
      • New potent gene editing tools to increase knock-in and knock-out efficiency
      • Addressing non-viral delivery barriers through protocol optimization

    Learning Objectives:

    • Current industry trends and challenges of cell and gene therapy manufacturing
    • Benefits of innovative new upstream technologies for virus generation in suspension

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    OCT 19, 2017 8:00 AM PDT

    WEBINAR: New viral and non-viral platforms for T-cell engineering


    Specialty

    Cancer Research

    Immunology

    Cell Biology

    Cancer Therapeutics

    Biotechnology

    Molecular Biology

    Cell Culture

    Cancer Diagnostics

    Oncology

    Biomarkers

    Gene Expression

    Immuno-Oncology

    Genetics

    Clinical Research

    Drug Discovery

    Geography

    North America56%

    Europe28%

    Asia6%

    South America3%

    Oceania2%

    Africa2%

    Registration Source

    Website Visitors100%

    Job Title

    Student17%

    Scientist15%

    Research Scientist13%

    Executive12%

    Facility/Department Manager11%

    Medical Doctor/Specialist6%

    Post Doc5%

    Medical Laboratory Technician4%

    Educator/Faculty3%

    Marketing/Sales3%

    Clinical Laboratory Scientist3%

    Lab Management2%

    Engineer2%

    QC/QA2%

    Biologist2%

    Chemist1%

    Consultant1%

    Organization

    Academic Institution9%

    Biotech Company8%

    Research Institute5%

    Clinical Laboratory4%

    Hospital3%

    Life Science Company3%

    Government2%

    Pharmaceutical Company2%

    Medical Center1%

    Ambulatory Care1%

    Consultant1%

    Contract Research Organization (Cro)1%

    Industrial Company1%

    Medical School1%

    Other2%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more